Lynn Tetrault

Track

Insider profile

Currently holds a position at Neogenomics Inc

Performance

Overall performance
2.7
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -12% 8.2% 15.1%
Success rate 36% 68% 82%
Transactions
4 25% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 38%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Director Neogenomics Inc June 12, 2015 -
Executive Vice President - Human Resources and Corporate Affairs AstraZeneca PLC May 1, 2007 - Jan. 1, 2013
Lynn Tetrault's trades of Rhythm Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
111.35
Quantity 87,534
Value US$2,973,021
Transaction date
Proposed sale
Price
102.18
Quantity 46,246
Value US$2,436,824
Transaction date
Sale
Price
11.10
Quantity 5,307 -5.8%
Value US$58,908
Transaction date
Proposed sale
Price
11.15
Quantity 5,307
Value US$59,173
Transaction date
Sale
Price
11.29
Quantity 5,307 -5.5%
Value US$59,916
Transaction date
Proposed sale
Price
10.95
Quantity 5,307
Value US$58,112
Transaction date
Purchase
Price
8.14
Quantity 7,000 +inf%
Value US$56,974
Transaction date
Proposed sale
Price
50.66
Quantity 17,501
Value US$886,601
Transaction date
Proposed sale
Price
45.26
Quantity 10,000
Value US$452,600
Transaction date
Sale
Price
15.97
Quantity 6,112 -10.9%
Value US$97,579
Transaction date
Proposed sale
Price
15.97
Quantity 6,112
Value US$97,609
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-22
PlS Planned sale
64,345 +27.3%
329.38
US$2,709,802 		64,345 +27.3% 329.38 US$2,709,802
2026-06-22 2026-06-22
PrS Proposed sale
87,534
111.35
US$2,973,021 		87,534 111.35 US$2,973,021
2026-06-22 2026-06-22
PrS Proposed sale
46,246
102.18
US$2,436,824 		46,246 102.18 US$2,436,824
2026-06-17 2026-06-15
S Sale
5,307 -5.8%
11.10
US$58,908 		5,307 -5.8% 11.10 US$58,908
2026-06-15 2026-06-15
PrS Proposed sale
5,307
11.15
US$59,173 		5,307 11.15 US$59,173
2026-06-11 2026-06-09
S Sale
5,307 -5.5%
11.29
US$59,916 		5,307 -5.5% 11.29 US$59,916
2026-06-09 2026-06-09
PrS Proposed sale
5,307
10.95
US$58,112 		5,307 10.95 US$58,112
2025-05-09 2025-05-09
B Purchase
7,000 +inf%
8.14
US$56,974 		7,000 +inf% 8.14 US$56,974
2024-09-11 2024-09-10
PlS Planned sale
350 -10.4%
50.60
US$17,710 		350 -10.4% 50.60 US$17,710
2024-09-11 2024-09-10
PlS Planned sale
8,661 -72.1%
50.20
US$434,796 		8,661 -72.1% 50.20 US$434,796
2024-09-11 2024-09-10
PlS Planned sale
8,490 -41.4%
49.05
US$416,418 		8,490 -41.4% 49.05 US$416,418
2024-09-10 2024-09-10
PrS Proposed sale
17,501
50.66
US$886,601 		17,501 50.66 US$886,601
2024-09-11 2024-09-09
PlS Planned sale
3,199 -51.6%
50.04
US$160,068 		3,199 -51.6% 50.04 US$160,068
2024-08-28 2024-08-26
PlS Planned sale
4,300 -58.9%
50.01
US$215,029 		4,300 -58.9% 50.01 US$215,029
2024-08-26 2024-08-26
PrS Proposed sale
7,499
46.12
US$345,854 		7,499 46.12 US$345,854
2024-08-14 2024-08-12
PlS Planned sale
407 -11.9%
45.37
US$18,466 		407 -11.9% 45.37 US$18,466
2024-08-14 2024-08-12
PlS Planned sale
9,593 -73.8%
44.62
US$427,996 		9,593 -73.8% 44.62 US$427,996
2024-08-12 2024-08-12
PrS Proposed sale
10,000
45.26
US$452,600 		10,000 45.26 US$452,600
2024-03-06 2024-03-04
S Sale
6,112 -10.9%
15.97
US$97,579 		6,112 -10.9% 15.97 US$97,579
2024-03-04 2024-03-04
PrS Proposed sale
6,112
15.97
US$97,609 		6,112 15.97 US$97,609